This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2017 Jul;96(7):1219-1220.

doi: 10.1007/s00277-017-3007-9. Epub 2017 Apr 22.

Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma

Yu-Yan Hwang¹, Pek-Lan Khong², Yok-Lam Kwong³

Affiliations

Affiliations

¹ Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China.
² Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China.
³ Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China. ylkwong@hkucc.hku.hk.

PMID: 28434018
DOI: 10.1007/s00277-017-3007-9

Case Reports

Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma

Yu-Yan Hwang et al. Ann Hematol. 2017 Jul.

. 2017 Jul;96(7):1219-1220.

doi: 10.1007/s00277-017-3007-9. Epub 2017 Apr 22.

Authors

Yu-Yan Hwang¹, Pek-Lan Khong², Yok-Lam Kwong³

Affiliations

¹ Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China.
² Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China.
³ Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China. ylkwong@hkucc.hku.hk.

PMID: 28434018
DOI: 10.1007/s00277-017-3007-9

No abstract available

PubMed Disclaimer

Similar articles

Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.
Zhao L, Yang Y, Li W, Li T, Gao Q. Zhao L, et al. Immunotherapy. 2018 Aug;10(11):913-917. doi: 10.2217/imt-2018-0025. Immunotherapy. 2018. PMID: 30149764 Review.
What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma.
Issa AK, Westin JR. Issa AK, et al. Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):483-487. doi: 10.1016/j.clml.2016.06.011. Epub 2016 Jun 8. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27364263
Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation.
Aslan A, Aras T, Özdemir E. Aslan A, et al. Leuk Lymphoma. 2017 Mar;58(3):754-755. doi: 10.1080/10428194.2016.1213835. Epub 2016 Aug 9. Leuk Lymphoma. 2017. PMID: 27687237 No abstract available.
γδ T cell clonal proliferation early after PD-1 blockade.
Ono K, Onishi Y, Kobayashi M, Hatta S, Nasu K, Watanabe S, Ichikawa S, Okitsu Y, Fukuhara N, Harigae H. Ono K, et al. Ann Hematol. 2019 Jan;98(1):219-220. doi: 10.1007/s00277-018-3406-6. Epub 2018 Jun 26. Ann Hematol. 2019. PMID: 29946908 No abstract available.
Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Dada R. Dada R. Ann Hematol. 2018 Apr;97(4):555-561. doi: 10.1007/s00277-017-3226-0. Epub 2018 Jan 10. Ann Hematol. 2018. PMID: 29322203 Review.

See all similar articles

Cited by

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.
Lepik KV, Fedorova LV, Kondakova EV, Zalyalov YR, Babenko EV, Lepik EE, Kotselyabina PV, Beynarovich AV, Popova MO, Volkov NP, Stelmakh LV, Baykov VV, Moiseev IS, Mikhailova NB, Kulagin AD, Afanasyev BV. Lepik KV, et al. Hemasphere. 2020 Sep 23;4(5):e480. doi: 10.1097/HS9.0000000000000480. eCollection 2020 Oct. Hemasphere. 2020. PMID: 33062947 Free PMC article.
Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory Hodgkin lymphoma.
Colunga-Pedraza PR, Vaquera-Alfaro HA, Guzmán-Martínez Z, Alemán-Jiménez MC, Vega-Mateos A, Gómez-De León A, Villela LM, Gómez-Almaguer D. Colunga-Pedraza PR, et al. Ann Hematol. 2024 Dec;103(12):5607-5614. doi: 10.1007/s00277-024-06098-9. Epub 2024 Nov 19. Ann Hematol. 2024. PMID: 39562359
Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.
Chang A, Schlafer D, Flowers CR, Allen PB. Chang A, et al. Expert Opin Investig Drugs. 2018 Jan;27(1):55-70. doi: 10.1080/13543784.2018.1416091. Epub 2017 Dec 24. Expert Opin Investig Drugs. 2018. PMID: 29228840 Free PMC article. Review.
Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review.
Macapagal SC, Lee H, Abdul Jabbar J, Fjorden AC, Joseph IT, Kaur R, Mostafa JA. Macapagal SC, et al. Cureus. 2022 Mar 24;14(3):e23452. doi: 10.7759/cureus.23452. eCollection 2022 Mar. Cureus. 2022. PMID: 35481332 Free PMC article. Review.
Low-dose PD-1 inhibition in relapsed/refractory classic Hodgkin lymphoma: systematic review and meta-analysis.
Akhmedov M, Zeynalova P, Fedenko A, Kaprin A. Akhmedov M, et al. Invest New Drugs. 2025 Jul 21. doi: 10.1007/s10637-025-01565-0. Online ahead of print. Invest New Drugs. 2025. PMID: 40690099 Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information